Abstract
We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).
Lingua originale | English |
---|---|
pagine (da-a) | e124- |
Numero di pagine | 1 |
Rivista | THE LANCET ONCOLOGY |
Volume | 21 |
Stato di pubblicazione | Published - 2020 |
All Science Journal Classification (ASJC) codes
- ???subjectarea.asjc.2700.2730???